Supernus Pharmaceuticals ... (SUPN)
31.54
-0.20 (-0.63%)
At close: Mar 04, 2025, 1:47 PM
Supernus Pharmaceuticals Cash Flow Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
| Net Income | 73.86M | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M | 14.02M | 19.87M | -92.27M | -46.28M | -23.23M | -39.08M | 4.14M | -33.48M | -17.27M |
| Depreciation & Amortization | 80.41M | 84.86M | 85.54M | 32.59M | 18.14M | 6.66M | 7.06M | 8.13M | 2.4M | 921K | 928K | 742K | 871K | 879K | 1.19M | 1.07M | 1.11M | 932.21K |
| Stock-Based Compensation | 27.75M | 26.76M | 17.57M | 17.91M | 16.56M | 14.85M | 11.29M | 8.43M | 5.93M | 4.23M | 2.72M | 1.91M | 443K | -82K | 297K | 111K | 99K | 74.1K |
| Other Working Capital | -4.92M | 2.27M | 29.14M | -3.9M | -56K | -21.13M | 44.05M | 47.89M | 24.81M | 15.79M | 2.28M | 8.23M | -951K | 1.24M | 64K | 360K | 21K | 227.64K |
| Other Non-Cash Items | 12.11M | 33M | 3.57M | 24.62M | 12.69M | 13.79M | 8.54M | -4.14M | 605K | 748K | 2.09M | 3.03M | 330K | 2.3M | -408K | 382.45K | 179K | n/a |
| Deferred Income Tax | -20.14M | -25.71M | -26.32M | -4.99M | 568K | -5.83M | -4.17M | 21.22M | -41.79M | 2.15M | -371K | 22.96M | 653K | -16.25M | -399K | -4.59M | n/a | n/a |
| Change in Working Capital | -2.05M | -9.14M | -24.24M | 3.57M | -36.52M | 613K | -4.73M | 23.71M | 8.45M | 10.06M | -17.5M | 5.67M | -3.21M | 188K | 5.85M | 1.52M | 2.44M | 2.29M |
| Operating Cash Flow | 171.95M | 111.08M | 116.83M | 127.13M | 138.4M | 143.13M | 128.99M | 114.64M | 66.81M | 32.12M | 7.73M | -57.95M | -47.2M | -36.19M | -32.54M | 2.63M | -29.65M | -13.98M |
| Capital Expenditures | -725K | -551K | -412K | -2.04M | -3.45M | -2.74M | -844K | -2.03M | -1.6M | -2.1M | -593K | -2.35M | -753K | -685K | -294K | -714K | -135K | -1.06M |
| Acquisitions | n/a | n/a | -14K | -311.69M | -313.54M | n/a | n/a | n/a | n/a | n/a | n/a | 705K | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -688.01M | -101.62M | -406.99M | -311.57M | -95.89M | -409.71M | -491.65M | -101.89M | -47.36M | -63.2M | -53.26M | -85.57M | -97.67M | -17.89M | -32.78M | -56.29M | -89.51M | -48.38M |
| Sales Maturities Of Investments | 498.86M | 370.9M | 190.74M | 530.51M | 378.42M | 253.17M | 79.83M | 28.66M | 31.82M | 37.58M | 53.47M | 75.81M | 49.47M | 26.87M | 58.9M | 28.62M | 105.13M | 64.3M |
| Other Investing Acitivies | 9K | n/a | 14K | 12.89M | -241K | 1.35M | -809K | -11.15M | -18.82M | -8.51M | -4.5M | -705K | -48.21M | 25.61M | n/a | n/a | n/a | n/a |
| Investing Cash Flow | -189.87M | 268.73M | -216.66M | -81.91M | -34.7M | -157.92M | -413.48M | -86.42M | -35.96M | -36.23M | -4.89M | -12.11M | -48.96M | 33.9M | 25.82M | -28.39M | 15.48M | 14.85M |
| Debt Repayment | n/a | -402.5M | n/a | -137.51M | -802K | n/a | 309.6M | n/a | n/a | n/a | n/a | 65.66M | -6.78M | 30M | n/a | n/a | 75M | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | -2.71M | -1.99M | -22.9M | n/a | n/a | n/a | 55.25M | n/a | n/a | n/a | -1K | -2.92M | -6.04M | -2.94M | -948K | 4.26M | -10.54M | n/a |
| Financial Cash Flow | 12.19M | -397.88M | -10.48M | -130.42M | 3.56M | 3.93M | 376.44M | 5.68M | 2.05M | 1.87M | 570K | 62.74M | 87.92M | 27.09M | -944K | 4.28M | 64.46M | 5K |
| Net Cash Flow | -5.72M | -18.07M | -110.31M | -85.21M | 107.26M | -10.87M | 91.94M | 33.91M | 32.9M | -2.24M | 3.42M | -7.32M | -8.24M | 24.8M | -7.67M | -21.47M | 50.29M | 878.56K |
| Free Cash Flow | 171.23M | 110.53M | 116.41M | 125.08M | 134.95M | 140.39M | 128.14M | 112.61M | 65.21M | 30.02M | 7.14M | -60.3M | -47.95M | -36.87M | -32.84M | 1.92M | -29.79M | -15.04M |